SAVE 30% ON EACH EBOOK AND 60% ON THE COMPLETE BUNDLE!
HSV Transmission Risk: What Studies Actually Show
See what studies show about HSV-2 transmission risk per act and over time, plus how condoms, valacyclovir and avoiding sex during symptoms reduce risk.
MEDICAL & WELLNESSTRANSMISSION & PREVENTION
Brandon Hart
5/30/20265 min read
There is no single transmission percentage that applies to every couple. Here is what the strongest HSV-2 studies show—and what condoms, suppressive treatment and symptom awareness can change.
The short answer
Genital herpes can pass to a partner when symptoms are present and during asymptomatic shedding, when the skin looks and feels normal. The risk is not identical for every person or every sexual encounter. It changes with the HSV type and infection site, how recently infection occurred, the direction of transmission, symptoms, frequency of sex, condom use and suppressive antiviral treatment.
In a major HSV-2 trial, daily valacyclovir reduced transmission among couples who also received safer-sex counselling and were offered condoms. The figures, study population and limits appear below; they cannot predict an individual couple’s risk.
For a practical plan, discuss suppressive antivirals with a clinician when appropriate, use condoms consistently, and avoid sexual contact during sores or warning symptoms. Each step can reduce risk in relevant circumstances, but none makes transmission impossible.
Why online transmission percentages often conflict
Figures are frequently taken from different studies and treated as if they describe the same situation. They may measure:
risk per sexual act rather than cumulative risk over several months;
symptomatic genital herpes rather than every laboratory-confirmed HSV-2 acquisition;
transmission from men to women rather than women to men;
couples with or without HIV;
people with established symptomatic HSV-2 rather than newly acquired infection;
reported condom use rather than perfectly consistent use.
A percentage is only useful when its population, time period and outcome are stated beside it.
What the valacyclovir trial found
In the eight-month randomized trial:
overall HSV-2 acquisition was 3.6% with placebo and 1.9% with daily valacyclovir;
symptomatic acquisition was 2.2% with placebo and 0.5% with valacyclovir;
HSV-2 was detected on 10.8% of sampled days with placebo and 2.9% with valacyclovir in the shedding substudy;
the average acquisition rate was 0.68 per 1,000 reported sexual contacts with placebo and 0.35 per 1,000 with valacyclovir.
These results apply most directly to couples resembling the study population: immunocompetent, heterosexual, HSV-2-discordant couples where the infected partner had recurrent symptomatic genital HSV-2. The trial does not establish an exact risk for every relationship, for genital HSV-1, or for people whose clinical circumstances are different.
What condom studies show
Condoms reduce HSV-2 transmission risk but cannot cover every area of potentially infectious skin.
A per-act analysis of 911 African couples affected by both HSV-2 and HIV-1 estimated 28.5 transmissions per 1,000 unprotected acts from men to women, the highest rate in that study. Reported condom use was associated with a 96% reduction in male-to-female per-act risk. The estimated reduction from women to men was 65%, although that result was of borderline statistical significance.
Those figures are valuable evidence that condoms help, but the study population differed from many couples seeking general HSV advice. The 28.5-per-1,000 estimate should not be presented as the default risk for every unprotected encounter.
The CDC recommends consistent condom use as part of risk reduction while explaining that condoms decrease rather than eliminate transmission.
Symptoms, prodrome and asymptomatic shedding
Transmission can occur when no sores are visible because HSV can be released from genital skin or mucosa without symptoms. Shedding is generally more frequent during the first year after acquiring HSV-2.
Avoid vaginal, anal and oral sex when sores are present or when warning symptoms such as tingling, burning or localized pain suggest an outbreak may be starting. This does not remove asymptomatic risk on other days, but it avoids the periods clinicians consider most concerning.
Genital HSV-1 and genital HSV-2 are different
Genital HSV-1 usually recurs and sheds less often than genital HSV-2 after the initial infection. A prospective study of first-episode genital HSV-1 found genital shedding on 12.1% of sampled days at around two months and 7.1% at around eleven months, with modelled rates showing a significant decline.
Direct transmission-prevention evidence for genital HSV-1 is much more limited. It is therefore unsafe to take an HSV-2 trial percentage and present it as a proven genital HSV-1 transmission rate. The CDC recommends reserving suppressive therapy for genital HSV-1 for people with frequent recurrences, using shared decision-making, because recurrences and shedding are generally lower and prevention-of-transmission data are lacking.
If a partner already has HSV antibodies
Partner testing can change the discussion, but results need careful interpretation. An HSV-2 antibody result generally implies anogenital infection. An HSV-1 antibody result does not show whether infection is oral or genital, and some commercial HSV-2 blood tests need confirmation when the index value is low.
Do not assume that a positive result automatically means there is no relevant transmission question. A clinician can interpret type-specific results, exposure timing, symptoms and test limitations for both partners.
Pregnancy requires separate advice
Pregnancy changes the clinical stakes. According to the CDC, the risk of neonatal transmission is highest when genital herpes is acquired near delivery and is low—below 1%—for women with established recurrent genital herpes or infection acquired during the first half of pregnancy.
Anyone who is pregnant, trying to conceive or whose partner is pregnant should tell the obstetric team about known or suspected genital herpes. Management depends on who has HSV, the type and site, when infection occurred, symptoms near labour and the clinician’s assessment.
A practical risk-reduction plan
For couples where one partner has genital HSV-2 and the other does not, evidence-based risk reduction can include:
Avoid sex during visible outbreaks and prodromal symptoms.
Use condoms consistently and correctly.
Discuss daily suppressive antiviral treatment with a clinician.
Confirm the HSV type and infection site where possible.
Discuss pregnancy plans early with the appropriate clinician.
Make decisions together using the limits of the evidence rather than a promise of zero risk.
No strategy makes sexual transmission impossible. Combining these measures can substantially reduce risk.
Common questions
Is HSV transmission risk ever zero?
No sexual activity involving potentially affected skin can be guaranteed risk-free. Risk can be reduced through symptom awareness, condoms and suppressive treatment where appropriate.
Does valacyclovir prevent all transmission?
No. In the major trial, daily valacyclovir reduced overall HSV-2 acquisition from 3.6% to 1.9% over eight months; it did not reduce the rate to zero.
Can herpes pass when there are no sores?
Yes. Asymptomatic shedding allows transmission without visible lesions. Shedding frequency varies by HSV type, time since infection and individual factors.
Are condoms useful if they do not cover all genital skin?
Yes. They reduce exposure and have been associated with lower HSV-2 transmission, especially from men to women, while leaving some uncovered skin-to-skin risk.
Can a website calculate my exact personal percentage?
Usually not. Published averages cannot incorporate every relevant factor, and the strongest studies cover specific populations. A clinician can help interpret the evidence for your circumstances but still cannot promise an exact outcome.
Primary sources
Corey et al.: Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes
Magaret et al.: Effect of Condom Use on Per-act HSV-2 Transmission Risk
Johnston et al.: Viral Shedding One Year Following First-Episode Genital HSV-1 Infection
Last reviewed: 6 October 2026. This article is for general education and is not a substitute for diagnosis, personalised medical advice or care from a qualified clinician.
MODERN HSV PLAYBOOK
THE SERIES
© 2026 Modern HSV Playbook. All rights reserved.
SITE
Content for informational purposes only. Not a substitute for professional medical advice.